Mitochondrial division inhibitor-1 treatment inhibits oxidative metabolism and thus lung cancer cell proliferation by mediating pathological ROS production and alterations in isocitrate dehydrogenase activity to reduce circulating levels of TCA. The gene discussed is IDH3A; the disease is lung cancer.